Bicara Therapeutics (BCAX) Equity Average (2023 - 2026)

Bicara Therapeutics has reported Equity Average for 4 years, with the latest figure at $457.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 3.73% year-over-year to $457.7 million; the trailing twelve-month figure through Mar 2026 stood at $457.7 million (down 3.73% YoY), and the FY2025 full-year result was $446.7 million, up 160.36% from the prior year.
• Equity Average for Q1 2026 stood at $457.7 million, up from $402.1 million in the prior quarter.
• The five-year high for Equity Average was $500.7 million in Q4 2024, with the low at -$167.4 million in Q2 2024.
• Historically, Equity Average has averaged $240.5 million across 4 years, with a median of $410.6 million in 2025.
• Annual changes were most pronounced in 2024 — Equity Average jumped 450.3% — and 2025, when it fell 19.69%.
• Bicara Therapeutics' Equity Average stood at -$142.9 million in 2023, then jumped by 450.3% to $500.7 million in 2024, then slipped by 19.69% to $402.1 million in 2025, then grew by 13.82% to $457.7 million in 2026.
• The last three Equity Average figures came in at $457.7 million (Q1 2026), $402.1 million (Q4 2025), and $419.0 million (Q3 2025), per Business Quant data.